Research progress of the discontinuation of thrombopoietin receptor agonist in patients with immune thrombocytopenia
-
-
关键词:
- 血小板生成素受体激动剂 /
- 免疫性血小板减少症 /
- 停药
Abstract: Immune thrombocytopenia(ITP) is an autoimmune hemorrhagic disease. Thrombopoietin-receptor agonists(TPO-RAs) are one of the best second-line treatment in ITP, providing long-term effectiveness and safety. However, long-term use of TPO-RA poses a hung burden in terms of potential adverse events and costs that limit the drug use in some patients. Studies abroad reported that 30% of patients who had stable platelet counts following TPO-RA treatment achieved sustained remission after discontinuation. In this regard, more clinicians paid attention to TPO-RA tapering and discontinuation. This article mainly summarized recent literature on TPO-RA tapering and discontinuation. -
-
[1] Zufferey A,Kapur R,Semple JW.Pathogenesis and therapeutic mechanisms in immune thrombocytopenia(ITP)[J].J Clin Med,2017,6(2):16.
[2] McMillan R,Bussel JB,George JN,et al.Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura[J].Am J Hematol,2008,83(2):150-154.
[3] Provan D,Arnold DM,Bussel JB,et al.Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood Adv,2019,3(22):3780-3817.
[4] 中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗的中国专家共识(2020版)[J].中华血液学杂志,2020,41(8):617-623.
[5] 中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗的中国专家共识(2016版)[J].中华血液学杂志,2016,37(2):89-93.
[6] Matzdorff A,Meyer O,Ostermann H,et al.Immune thrombocytopenia-current diagnostics and therapy:recommendations of a joint working group of DG-HO,ÖGHO,SGH,GPOH,and DGTI[J].Oncol Res Treat,2018,41(Suppl 5):1-30.
[7] Neunert C,Terrell DR,Arnold DM,et al.American Society of Hematology 2019guidelines for immune thrombocytopenia[J].Blood Adv,2019,3(23):3829-3866.
[8] Aslam R,Kapur R,Segel GB,et al.The spleen dictates platelet destruction anti-platelet antibody production and lymphocyte distribution patterns in a murine model of immune thrombocytopenia[J].Exp Hematol,2016,44(10):924-930.
[9] 张瑜,俞立虹,沈建平,等.重组人血小板生成素对难治性原发免疫性血小板减少症的维持治疗[J].浙江实用医学,2018,23(2):154-156.
[10] 中国临床肿瘤学会抗淋巴瘤联盟,中国抗癌协会癌症康复与姑息治疗专业委员会,中华医学会血液学分会.重组人白介素-11治疗血小板减少症临床应用中国专家共识(2018年版)[J].临床肿瘤学杂志,2018,23(3):260-266.
[11] Di Buduo CA,Currao M,Pecci A,et al.Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation[J].Haematologica,2016,101(12):1479-1488.
[12] Kuter DJ,Newland A,Chong BH,et al.Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia(ITP)for up to 1year and in those with chronic ITP for more than 1year:a subgroup analysis of integrated data from completed romiplostim studies[J].Br J Haematol,2019,185(3):503-513.
[13] Wong RSM,Saleh MN,Khelif A,et al.Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag:final results of the EXTENDstudy[J].Blood,2017,130(23):2527-2536.
[14] Ghadaki B,Nazi I,Kelton JG,et al.Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists[J].Transfusion,2013,53(11):2807-2812.
[15] Mahevas M,Fain O,Ebbo M,et al.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia.Results of a French observational study[J].Br J Haematol,2014,165(6):865-869.
[16] Gonzalez-Lopez TJ,Pascual C,Alvarez-Roman MT,et al.Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia[J].Am J Hematol,2015,90(3):E40-E43.
[17] Newland A,Godeau B,Priego V,et al.Remission and platelet responses with romiplostim in primary immune thrombocytopenia:final results from a phase 2study[J].Br J Haematol,2016,172(2):262-273.
[18] Gonzalez-Lopez TJ,Fernandez-Fuertes F,Pascual Lzquierdo MC,et al.Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia:8-Year Follow-up Data from 15Spanish Centers[J].Blood,2019,134(Supplement_1):2352.
[19] Cervinek L,Mayer J,Doubek M.Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults[J].Int J Hematol,2015,102(1):7-11.
[20] Marshall AL,Scarpone R,De Greef M,et al.Remissions after long-term use of romiplostim for immune thrombocytopenia[J].Haematologica,2016,101(12):e476-e478.
[21] Mazzucconi MG,Santoro C,Baldacci E,et al.TPO-RAs in pITP:description of a case series and analysis of predictive factors for response[J].Eur J Haematol,2017,98(3):242-249.
[22] Lozano ML,Mingot-Castellano ME,Perera MM,et al.Deciphering predictive factors for choice of thrombopoietin receptor agonist,treatment free responses,and thrombotic events in immune thrombocytopenia[J].Sci Rep,2019,9(1):16680.
[23] Iino M,Sakamoto Y,Sato T.Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia:an observational retrospective analysis in real-world clinical practice[J].Int J Hematol,2020,112(2):159-168.
[24] Zaja F,Carpenedob M,Baratèc C,et al.Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia:Real-world recommendations[J].Blood Rev,2020,41:100647.
[25] Bao W,Bussel JB,Heck S,et al.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J].Blood,2010,116(22):4639-4645.
[26] Nishimoto T,Numajiri M,Nakazaki H,et al.Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia[J].Int J Hematol,2014,100(4):341-344.
[27] Li MO,Sanjabi S,Flavell RA.Transforming growth factor-beta controls development homeostasis and tolerance of T cells by regulatory T cell-dependent and-independent mechanisms[J].Immunity,2006,25(3):455-471.
[28] Gudbarandsdottir S,Ghanima W,Nieslsen Claus H,et al.Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia(ITP)[J].Platelets,2017,28(5):478-483.
[29] Guilliams M,Bruhns P,Saeys Y,et al.The function of Fcγreceptors in dendritic cells and macrophages[J].Nat Rev Immunol,2014,14(2):94-108.
[30] Liu XG,Liu S,Feng Q,et al.Thrombopoietin receptor agonists shift the balance of Fcγreceptors toward inhibitory receptor IIb on monocytes in ITP[J].Blood,2016,128(6):852-861.
[31] Kapur R,Aslam R,Speck ER,et al.Thrombopoietin receptor agonist(TPO-RA)treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia(ITP)[J].Platelets,2020,31(3):399-402.
-
计量
- 文章访问数: 191
- PDF下载数: 450
- 施引文献: 0
下载: